SGNSTNV-001 (Seagen, Inc.)
Description: A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Target Patient Population: All solid tumors.
Study Design: Drug is administered IV Day 1, 8 and 15 of a 21 day cycle
Phone: (800) 411-7999
SGNSTNV-001 (Seagen, Inc.)
Description: A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Target Patient Population: All solid tumors.
Study Design: Drug is administered IV Day 1, 8 and 15 of a 21 day cycle